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Research article 
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Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disease. One of 
the major challenges in studying this progressive neurological disorder is to identify and develop 
biomarkers for early detection. Recently, several blood-based microRNA (miRNA) biomarkers for 
PD have been reported. However, follow-up studies with new, independent cohorts have been rare.  
Previously, we identified a panel of four circulating miRNA biomarkers for PD (miR-1826, 
miR-450b-3p, miR-505, and miR-626) with biomarker performance of 91% sensitivity and 100% 
specificity. However, the expression of miR-450b-3p could not be detected in a new, independent 
validation set. In our current study, we improved the detection power by including a non-biased 
pre-amplification step in quantitative real-time PCR (qRT-PCR) and reevaluated the biomarker 
performance. We found the panel of four PD-related miRNAs achieved the predictive power of 83% 
sensitivity and 75% specificity in our validation set. This is the first biomarker validation study of 
PD which showed reproducibility and robustness of plasma-based circulating miRNAs as molecular 
biomarkers and qRT-PCR as potential diagnostic assay. 
Keywords: Parkinson’s disease; circulating microRNAs; plasma; biomarkers; validation; 
quantitative real-time PCR 
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1. Introduction  
Parkinson’s disease (PD) is a complex and heterogeneous neurological disorder involving both 
progressive loss of dopaminergic neurons and intraneuronal aggregation of the protein 
alpha-synuclein. Its current diagnosis is based primarily on subjective clinical rating scales such as 
the Unified Parkinson’s disease rating scale, applicable only in the presence of its motor symptoms. 
However, it is well known that by the time of diagnosis, neurodegeneration has already reached a 
fairly advanced stage. Hence, there is an urgent need to develop biomarkers that are objective and 
measurable for early detection of PD. 
MicroRNAs (miRNAs) are small, conserved RNAs that mediate post-translational gene 
regulations. They are involved in many essential biological processes such as cell development, 
differentiation, proliferation, and apoptosis. The unique characteristics of miRNAs include 
tissue-specificity, high stability, quantifiability, and ease of isolation, making them ideal candidates 
for biomarker development.  
miRNAs that are associated with PD have been reported in the peripheral blood [1,2]. We 
demonstrated in a proof-of-concept study that plasma-based circulating miRNAs can distinguish 
PD patients from healthy controls and are potential molecular biomarkers for PD [3]. It was then 
followed by several other PD-related biomarker studies in serum, plasma, and cerebral spinal   
fluid [4–8]. None of these studies have reported a follow-up replication and validation study except 
ours. However, one of the biomarkers (from a panel of four) was not detectable in our previous 
validation study, making the biomarker performance unavailable. 
Validation of candidate biomarkers is one of the biggest challenges in biomarker research [9]. 
A validation study of potential biomarker candidates can provide a “gauge” for a go or no- go 
decision to move forward and develop these biomarkers into clinical assays, in our case, a diagnostic 
test for PD. In this study, we improved the detection power of miRNA biomarkers using a 
non-biased pre-amplification step and reassessed the performance of potential PD biomarkers in a 
validation set. This is the first reported validation study for plasma-based biomarkers in PD. We 
showed reproducibility and comparable sensitivity and specificity using circulating miRNAs as 
potential molecular biomarkers for PD. 
2. Materials and Method 
2.1. Study subjects  
PD patients and healthy controls were recruited at the Department of Neurology at Umeå 
University Hospital in Sweden. In addition, progressive supranuclear palsy (PSP) and multiple 
system atrophy (MSA) patients were also recruited as non-PD controls. All subjects agreed to 
participate by providing their informed consent forms and this study was approved by the 
institutional review board. The validation set in this study was composed of 30 PD (10 early- 
diagnosed –– PD-E and 20 advanced PD –– PD-L), 7 healthy controls, 5 PSP, and 4 MSA (Table 1). 
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Table 1.  Characteristics of study subjects for PD biomarker validation set 
  PD Healthy Controls PSP MSA
Sample size 
Age 
Hoehn & Yahr 
16 M 14 F 
69.4 ± 9.0 
2.2 ± 0.7 
3 M 4 F 
72.3 ± 3.4 
2 M   3 F 
75.2 ± 8.8 
4 ± 1.2 
2 M   2 F 
72.5 ± 17.8 
4.5 ± 1.0 
PD = Parkinson’s disease; PSP = progressive supranuclear palsy;  
MSA = multiple system atrophy; M = Male; F = Female 
2.2. Sample collection and RNA isolation 
Peripheral blood samples were obtained in 10 ml EDTA blood collection tubes and centrifuged 
at 4 °C at 1,000g for 15 min. Plasma was collected from the supernatant and store in 500 µl aliquots 
at −80 °C until further analysis. Total RNA including miRNAs was isolated from plasma using a TRI 
reagent RT-blood kit (Molecular Research Center). The quality and quantity of RNA were evaluated 
by RNA 6000 pico kits using a BioAnalyzer (Agilent). 
2.3. Quantitative real-time PCR (qRT-PCR) analysis 
miRNA expression of miR-1826, miR-450b-3p, miR-505, and miR-626 was evaluated using 
Taqman miRNA-specific assays (Life Technologies) [3]. An additional pre-amplification of reverse 
transcription product prior qRT-PCR step was executed according to Kroh et al. [10] with slight 
modification to improve detection sensitivity. qRT-PCR was performed in a MX3000P QPCR system 
(Agilent). MiR-15b was used as an endogenous control. The expression of each target miRNA is 
calculated relative to the endogenous control as ΔCT (delta cycle threshold). Higher value of ΔCT 
means lower miRNA expression and vice versa. Comparative CT (ΔΔCT) method was used to 
determine the differential miRNA expression [11]. Student t-test was performed and P < 0.05 was 
considered as statistically significant. 
2.4. Biomarker performance analysis 
Receiver operating characteristics (ROC) curve analysis was performed to summarize the 
accuracy of biomarker predictions, with an AUC (area under the curve) value close to 1 indicating an 
excellent diagnostic test [12]. This analysis was performed to confirm the ability of our candidate 
biomarkers to classify PD vs. controls correctly regardless of their specific thresholds. We then used 
95% normalized ΔCT values of individual miRNAs as optimal thresholds for classifying PD and 
healthy controls. 
3. Results 
3.1. Validation study of circulating miRNA biomarkers by qRT-PCR 
The expression of all circulating miRNA biomarkers (miR-1826, miR-450b-3p, miR-505, and 
miR-626) could be detected using qRT-PCR. ΔCT values for each biomarker were calculated and 
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compared among the experimental groups (Figures 1–4). ΔCT of miR-450b-3p in PD was 
statistically significant (P < 0.032) when compared with healthy controls. On the other hand, ΔCT for 
miR-1826 in PSP was statistically significant (P < 0.045) when compared with healthy controls. We 
also separated PD into PD-E (early-diagnosed, non-medicated) and PD-L (advanced PD, medicated) 
for further analysis. Interestingly, we found ΔCT of miR-1826 and miR-450b-3p statistically 
significant in PD-L when compared with healthy controls (P < 0.036 and P < 0.039, respectively) but 
not in PD-E vs. controls. ΔCT of miR-626 was found significant in PD-L and all PD (PD-E + PD-L) 
(P < 0.026 and P < 0.027, respectively) only when MSA and PSP were combined as a single group 
of non-PD. ΔΔCT values of each miRNA for all PD vs. healthy controls, MSA, or PSP were 
presented in Table 2. 
 
Figure 1. miRNA expression levels of circulating miR-1826 in healthy controls 
(CTR), Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive 
supranuclear palsy (PSP) patients. * Statistically significance between groups     
(P < 0.05). 
 
Figure 2. miRNA expression levels of circulating miR-450b-3p in healthy controls 
(CTR), Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive 
supranuclear palsy (PSP) patients. * Statistically significance between groups (P < 
0.05). 
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Figure 3. miRNA expression levels of circulating miR-505 in healthy controls (CTR), 
Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive 
supranuclear palsy (PSP) patients. 
 
Figure 4. miRNA expression levels of circulating miR-626 in healthy controls (CTR), 
Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive 
supranuclear palsy (PSP) patients. 
3.2. Circulating miRNA biomarker performance 
ROC analysis confirmed that the panel of four PD-related biomarkers has the ability to correctly 
predict PD and healthy controls. In this validation study, the optimal ΔCT threshold for each 
individual miRNAs: miR-1826, miR-450b-3p, miR-505, and miR-626, are 10, 18, 4, and 18, 
respectively. Since miR-1826 and miR-450b-3p were identified by the k-TSP (k-Top Scoring Pairs) 
algorithm [13], they always worked as a pair and only when the expression of miR-1826 > 
miR-450b-3p (ΔCT of miR-1826 < miR-450b-3p), PD is predicted. The combined predictive power 
of all four biomarkers for PD is 83% sensitivity, 75% specificity, 94% positive predicted value, and 
60% negative predicted value. 
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Table 2. Average ΔΔCT in log2 fold change for miRNA-1826,  
miR-450b-3p, miR-505, and miR-626 
  CTR MSA PSP 
PD miR-1826 
miR-450b-3p 
miR-505 
miR-626 
2.046 
−9.355 
−1.260 
0.326 
1.055 
−2.857 
1.316 
5.125 
−1.613 
−1.920 
−1.067 
3.918 
MSA miR-1826 
miR-450b-3p 
miR-505 
miR-626 
1.939 
−3.274 
−1.659 
−15.698 
  −1.702 
 1.488 
−1.405 
−1.308 
PSP miR-1826 
miR-450b-3 
miR-505 
miR-626 
3.300 
−4.874 
−1.181 
−12.000 
   
PD = Parkinson’s disease; CTR = healthy controls; MSA = multiple system atrophy;  
PSP =progressive supranuclear palsy 
4. Discussion 
Molecular biomarker discoveries for PD have been emerging rapidly for the last few years. 
However, insufficient follow-up validation studies, coupled with non-standardized molecular assays, 
have resulted in a stagnancy of biomarker development for PD. In addition, biomarker validation is 
known as a “tar pit” [14] as the majority of biomarker candidates were not reproducible and hence 
failed to move forward to preclinical or clinical settings. Therefore, the validation study presented 
here is the first step to reaffirm the potential use of circulating miRNAs as molecular biomarkers for 
PD. 
In this study, we reevaluated the performance of a panel of four circulating miRNAs as 
molecular biomarkers for PD in a previously tested validation set. Previously, the overall biomarker 
performance could not be obtained due to lack of detection in one of the biomarkers. Here, we 
improved the sensitivity of detection using a known, non-biased pre-amplification step which 
enabled all circulating miRNA biomarkers to be validated by qRT-PCR. We found 1) miRNA 
expression of individual biomarkers such as miR-450b-3p and miR-1826 could significantly 
differentiate PD and PSP patients from healthy controls, 2) combination of 4 biomarkers brought the 
predictive power to 83% sensitivity and 75% specificity in the validation set, which is lower when 
compared with the replication set, 3) no statistical significance could be found in the miRNA 
expression of all investigated biomarkers between PD vs. PSP and PD vs. MSA, and 4) miR-1826 
expression was significantly higher in PD-L than healthy controls and vice versa for miR-450b-3p, 
but not in PD-E vs. healthy controls. 
Although the biomarker predictive power was not as high as the discovery and replication sets, 
the performance was reproducible in the validation set. Further, this validation study was performed 
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in a different laboratory setting with different qRT-PCR equipment, further demonstrating potential 
high reproducibility for this assay using a variety of qRT-PCR instrumentation. Hence, our validation 
study confirmed the reproducibility and robustness of circulating miRNAs as molecular biomarkers 
as well as using the qRT-PCR assay as a potential molecular diagnostic tool. Future plans include 
further evaluation with digital PCR for cross-platform validation studies. 
We included MSA and PSP as non-PD controls (MSA and PAP) in the validation study and 
found that the panel of 4 PD-related biomarkers could not significantly differentiate PD from MSA 
or PSP (except when MSA and PSP were combined into one group as non-PD, then expression of 
miR-626 was significantly higher in PD-L and PD-E + PD-L than non-PD). Larger sample size for 
non-PD controls is required to confirm whether these biomarkers can be used to differentiate non-PD 
from PD or are more appropriate to target movement disorders-related neurodegenerative disease in 
general.  For the same reason (small sample size), it is also uncertain whether the difference in 
miRNA expression between early diagnosed, naïve PD patients vs. advanced, medicated PD patients 
are due to their disease stages and/or medication or merely lack of statistical power. 
As noted, small sample size is a major limitation in this validation study. Even so, our findings 
are promising as we confirmed the validity of the biomarkers as well as the diagnostic assay. It 
would be reasonable to consider performing a much larger validation study from the same and/or a 
new, independent collection site to further test the performance and robustness of these biomarkers. 
It is also worth considering the assembly of PD-related circulating miRNAs from different reports to 
build a more comprehensive biomarker panel that may further improve prediction sensitivity and 
specificity. 
5. Conclusion 
We reported the first validation study of PD-related plasma-based circulating miRNA 
biomarkers using qRT-PCR and confirmed the validity of the biomarkers and the molecular assay. 
Implementing vigorous validation studies will ensure development of reliable and robust disease 
biomarkers before translation into clinical applications. 
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